• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by LeMaitre Vascular Inc.

    3/27/26 10:21:11 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care
    Get the next $LMAT alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 6)


    LeMaitre Vascular Inc

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)




    525558201

    (CUSIP Number)
    03/13/2026

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)




    schemaVersion:


    SCHEDULE 13G

    CUSIP Number(s):
    525558201


    1Names of Reporting Persons

    The Vanguard Group
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    PENNSYLVANIA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0 %
    12Type of Reporting Person (See Instructions)

    IA

    Comment for Type of Reporting Person:   On January 12, 2026, The Vanguard Group, Inc. went through an internal realignment. In accordance with SEC Release No. 34-39538 (January 12, 1998), certain subsidiaries or business divisions of subsidiaries of The Vanguard Group, Inc., that formerly had, or were deemed to have, beneficial ownership with The Vanguard Group, Inc., will report beneficial ownership separately (on a disaggregated basis) from The Vanguard Group, Inc. in reliance on such release. These subsidiaries and/or business divisions pursue the same investment strategies as previously pursued by The Vanguard Group, Inc. prior to the realignment. Further in accordance with SEC Release No. 34-39538 (January 12, 1998), The Vanguard Group, Inc. no longer has, or is deemed to have, beneficial ownership over securities beneficially owned by such subsidiaries and/or business divisions.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    LeMaitre Vascular Inc
    (b)Address of issuer's principal executive offices:

    63 2nd Avenue, Burlington, MA, 01803
    Item 2. 
    (a)Name of person filing:

    The Vanguard Group
    (b)Address or principal business office or, if none, residence:

    100 Vanguard Blvd.,, Malvern, PA, 19355
    (c)Citizenship:

    PA
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    0
    (b)Percent of class:

    0  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    0

     (ii) Shared power to vote or to direct the vote:

    0

     (iii) Sole power to dispose or to direct the disposition of:

    0

     (iv) Shared power to dispose or to direct the disposition of:

    0

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required.


    The Vanguard Group, including investment companies registered under the Investment Company Act of 1940 and other managed accounts, have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the securities reported herein.No one other person's interest in the securities reported herein is more than 5%.
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    The Vanguard Group
     
    Signature:Ashley Grim
    Name/Title:Head of Global Fund Administration
    Date:03/27/2026
    Get the next $LMAT alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LMAT

    DatePrice TargetRatingAnalyst
    8/6/2025$95.00Mkt Perform → Outperform
    Barrington Research
    2/28/2025Outperform → Perform
    Oppenheimer
    2/28/2025Outperform → Mkt Perform
    Barrington Research
    2/13/2025$95.00Equal Weight
    Wells Fargo
    10/15/2024$96.00Neutral
    Cantor Fitzgerald
    8/2/2024$85.00 → $105.00Buy
    Lake Street
    5/31/2024$100.00Buy
    ROTH MKM
    4/26/2024$59.00 → $75.00Hold → Buy
    Stifel
    More analyst ratings

    $LMAT
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    LeMaitre to Participate at Upcoming Investor Conferences in March

    BURLINGTON, Mass., Feb. 27, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that management will be participating in five upcoming investor conferences in March. Leerink Partners Global Healthcare ConferenceTuesday, March 10, 2026W South Beach, MiamiManagement will present at 1:00 PM EDT Citizens Life Sciences ConferenceWednesday, March 11, 2026Eden Roc Miami Beach, MiamiManagement will present at 1:40 PM EDT Barclays Annual Global Healthcare ConferenceThursday, March 12, 2026Management will be available for 1x1 meetings KeyBanc Capital Markets Healthcare ForumTuesday, March 17, 2026VirtualManagement will present at 3:45 PM EDT 38th Annual ROTH Conferenc

    2/27/26 2:50:37 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    LeMaitre Q4 2025 Financial Results

    BURLINGTON, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants, and services, today reported Q4 2025 results, announced a quarterly dividend of $0.25/share (+25%), and provided guidance. Q4 2025: Sales $64.5mm, +16% (+15% organic) vs. Q4 2024Gross margin 71.7% (+240 bps)Op. income $18.8mm (+47%)Op. margin 29%Diluted EPS $0.68 (+39%)Cash up $16.1mm sequentially to $359.1mm Grafts (+27%), valvulotomes (+20%), and carotid shunts (+18%) drove Q4 sales growth. EMEA sales increased 29%, APAC 20%, and the Americas 10%. Gross margin of 71.7% (+240 bps) increased due to higher average selling prices and manufacturing efficien

    2/25/26 4:05:00 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    LeMaitre Will Announce Fourth Quarter 2025 Earnings Results February 25, 2026

    BURLINGTON, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its fourth quarter 2025 financial results on Wednesday, February 25, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and services for t

    2/11/26 9:47:47 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    $LMAT
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Senior V. P., Operations Kamke Trent G exercised 2,625 shares at a strike of $35.48 and sold $284,812 worth of shares (2,625 units at $108.50) (SEC Form 4)

    4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)

    3/13/26 4:42:58 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    President and Director Roberts David B sold $356,586 worth of shares (3,312 units at $107.68), decreasing direct ownership by 18% to 14,667 units (SEC Form 4)

    4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)

    3/13/26 4:42:12 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    Chief Financial Officer Leblanc Dorian Paul converted options into 2 shares and covered exercise/tax liability with 96 shares, decreasing direct ownership by 4% to 2,302 units (SEC Form 4)

    4 - LEMAITRE VASCULAR INC (0001158895) (Issuer)

    3/12/26 4:12:03 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    $LMAT
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by LeMaitre Vascular Inc.

    SCHEDULE 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)

    3/27/26 10:21:11 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    SEC Form 10-K filed by LeMaitre Vascular Inc.

    10-K - LEMAITRE VASCULAR INC (0001158895) (Filer)

    2/26/26 7:01:03 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    LeMaitre Vascular Inc. filed SEC Form 8-K: Results of Operations and Financial Condition

    8-K - LEMAITRE VASCULAR INC (0001158895) (Filer)

    2/25/26 4:54:33 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    $LMAT
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Lemaitre Vascular upgraded by Barrington Research with a new price target

    Barrington Research upgraded Lemaitre Vascular from Mkt Perform to Outperform and set a new price target of $95.00

    8/6/25 7:37:02 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    Lemaitre Vascular downgraded by Oppenheimer

    Oppenheimer downgraded Lemaitre Vascular from Outperform to Perform

    2/28/25 8:28:09 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    Lemaitre Vascular downgraded by Barrington Research

    Barrington Research downgraded Lemaitre Vascular from Outperform to Mkt Perform

    2/28/25 7:39:54 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    $LMAT
    Financials

    Live finance-specific insights

    View All

    LeMaitre Q4 2025 Financial Results

    BURLINGTON, Mass., Feb. 25, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants, and services, today reported Q4 2025 results, announced a quarterly dividend of $0.25/share (+25%), and provided guidance. Q4 2025: Sales $64.5mm, +16% (+15% organic) vs. Q4 2024Gross margin 71.7% (+240 bps)Op. income $18.8mm (+47%)Op. margin 29%Diluted EPS $0.68 (+39%)Cash up $16.1mm sequentially to $359.1mm Grafts (+27%), valvulotomes (+20%), and carotid shunts (+18%) drove Q4 sales growth. EMEA sales increased 29%, APAC 20%, and the Americas 10%. Gross margin of 71.7% (+240 bps) increased due to higher average selling prices and manufacturing efficien

    2/25/26 4:05:00 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    LeMaitre Will Announce Fourth Quarter 2025 Earnings Results February 25, 2026

    BURLINGTON, Mass., Feb. 11, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT) announced today that it will release its fourth quarter 2025 financial results on Wednesday, February 25, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook. Access to the live call is available by registering online here. All registrants will receive dial-in information and a PIN allowing them to access the live call. The audio webcast can also be accessed live or via replay at www.lemaitre.com/investor. About LeMaitre LeMaitre is a provider of devices, implants, and services for t

    2/11/26 9:47:47 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    LeMaitre Q3 2025 Financial Results

    BURLINGTON, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of vascular devices, implants, and services, today reported Q3 2025 results, announced a quarterly dividend of $0.20/share, and provided guidance. Q3 2025 results include a non-recurring benefit from the Employee Retention Tax Credit. Non-GAAP adjusted figures exclude this benefit. A reconciliation of GAAP to non-GAAP results is included. Q3 2025: Sales $61.0mm, +11% (+12% organic)Gross margin 75.3% (+750 bps), adjusted 70.8% (+300 bps)Op. income $20.3mm (+54%), adjusted $16.9mm (+29%)Op. margin 33%, adjusted 28%Diluted EPS $0.75 (+54%), adjusted $0.62 (+27%)Cash up $23.6mm sequentiall

    11/6/25 4:05:00 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    $LMAT
    Leadership Updates

    Live Leadership Updates

    View All

    Anteris Appoints David Roberts and Gregory Moss to its Board of Directors

    MINNEAPOLIS and BRISBANE, Australia, June 09, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ:AVR, ASX: AVR)) a global structural heart company committed to designing, developing, and commercializing cutting-edge medical devices to restore healthy heart function, today announced the appointments of Mr. David Roberts and Mr. Gregory Moss to its Board of Directors. The Company also announced the resignation of Dr. Wenyi Gu from the Board upon completion of his term as an Australia-based non-executive director. "On behalf of the management team and Board, I am delighted to welcome David and Gregory to the Company" commented John Seaberg, Chairman o

    6/9/25 10:52:06 PM ET
    $AVR
    $LMAT
    Industrial Specialties
    Health Care
    Medical/Dental Instruments

    Precision Optics Appoints Joseph P. Pellegrino, Jr. to Board of Directors

    GARDNER, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Precision Optics Corporation, Inc. (NASDAQ:POCI), a leading designer and manufacturer of advanced optical instruments for the medical and defense/aerospace industries, is pleased to announce the appointment of Joseph P. "JJ" Pellegrino, Jr. to its Board of Directors. Mr. Pellegrino, who will also serve as Chairman of the Board's Audit Committee, brings decades of operational and financial experience as well as an extensive knowledge of the medical device industry to the board. Mr. Pellegrino most recently served as Chief Financial Officer of LeMaitre Vascular, Inc. (NASDAQ:LMAT), a provider of devices, implants and services for the treatm

    3/20/25 9:00:00 AM ET
    $LMAT
    $POCI
    Medical/Dental Instruments
    Health Care
    Biotechnology: Electromedical & Electrotherapeutic Apparatus

    Former Johnson & Johnson Executive Joins Advisory Board at Maitri Health Technologies

    Bridget Ross brings extensive experience in MedTech development and services;Joins advisory board of healthcare, logistics, capital markets and innovation leaders VANCOUVER, BC, March 23, 2021 /PRNewswire/ - Maitri Health Technologies Corp. ("Maitri") (CSE: MTEC) (FRA: D84), a global platform for healthcare supply security, today announced the appointment of Bridget Ross to its Advisory Board. Ms. Ross is currently CEO of ChroniSense Medical, Ltd., an Israel-based MedTech company and maker of wearable, medical-grade disease management devices. Ms. Ross serves as a Board Director for LeMaitre Vascular Inc. (NASDAQ: LMAT) and as a mentor for early stage MedTech companies through MassMEDIC and

    3/23/21 8:00:00 AM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    $LMAT
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by LeMaitre Vascular Inc.

    SC 13G - LEMAITRE VASCULAR INC (0001158895) (Subject)

    10/22/24 3:49:21 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by LeMaitre Vascular Inc. (Amendment)

    SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)

    2/13/24 5:08:02 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care

    SEC Form SC 13G/A filed by LeMaitre Vascular Inc. (Amendment)

    SC 13G/A - LEMAITRE VASCULAR INC (0001158895) (Subject)

    2/12/24 3:02:21 PM ET
    $LMAT
    Medical/Dental Instruments
    Health Care